US · 21 CFR
21 CFR 212.110
How must I maintain records of my production of PET drugs?
21 CFR Part 212 › Subpart L—Records
조항 원문
(a) Record availability. Records must be maintained at the PET drug production facility or another location that is reasonably accessible to responsible officials of the production facility and to employees of FDA designated to perform inspections.
(b) Record quality. All records, including those not stored at the inspected establishment, must be legible, stored to prevent deterioration or loss, and readily available for review and copying by FDA employees.
(c) Record retention period. You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product.
본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.
출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16